"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
| Descriptor ID |
D053614
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
|
| Concept/Terms |
Janus Kinase 2- Janus Kinase 2
- JAK-2 Protein Tyrosine Kinase
- JAK 2 Protein Tyrosine Kinase
- JAK2 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".
This graph shows the total number of publications written about "Janus Kinase 2" by people in this website by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 0 | 5 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 6 | 0 | 6 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.
-
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022 05 05; 139(18):2797-2815.
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
-
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019 05; 33(5):1287-1291.
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
-
PD-L1 Status in Refractory Lymphomas. PLoS One. 2016; 11(11):e0166266.
-
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2016 Sep; 27(6):648-52.
-
Specific dephosphorylation of Janus Kinase 2 by protein tyrosine phosphatases. Proteomics. 2015 Jan; 15(1):68-76.
-
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol. 2015 Apr; 94(4):717-9.
-
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One. 2014; 9(7):e99017.
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.